Altair Engineering Inc is a provider of enterprise-class engineering software enabling origination of entire product lifecycle from concept design to in-service operation. The integrated suite of software provided by the company optimizes design performance across multiple disciplines encompassing structures, motion, fluids, thermal management, system modeling and embedded systems. The company operates through two reportable segments i.e. Software which includes the portfolio of software products such as solvers and optimization technology products, modeling and visualization tools, industrial and concept design tools, and others; and Client Engineering Services which provides client engineering services to support customers. Most of the company's revenue comes from the United States.
| Website: | www.altair.com |
| Email: | ir@altair.com |
| Main Phone: | +1 248 614-2400 |
| Address: | 1820 East Big Beaver Road |
| State: | MI |
| City / Town: | Troy |
| Country: | USA |
| Postal Code: | 48083 |
| Exchange: | NGS |
| CEO: | James R. Scapa |
| Employees: | 2850 |
| NAICS: | Computer and Computer Peripheral Equipment and Software Merchant Wholesalers(423430) |
Investment decisions should be made to maximize expected total returns relative to risk tolerance.
The most successful consumer goods companies over the past several decades sell products that are used and replaced; are ubiquitous and have a strong brand name.
Yes, there is a difference.
Here's how to turn $4,000 into $1 million...but you have to be patient.
Leading biotechnology company, InVivo Therapeutics, is up 24% following positive developments in their ongoing spinal cord injury study.
It's becoming the equivalent of the "dog ate my homework" excuse during earnings reporting season.
Medical technology is not considered a huge-margin investment in the way that the biotech and drug industries are. However, some of today's medtech blurs the line, including hybrid companies
It's all about the fundamentals for Jason Napodano, CFA, of Zacks Investment Research. Revenue and earnings at the big biotechs are signaling investors that the market is still strong, and
Over the first six months of 2015, the market has not performed very well. Since the 1st of the year, the DJIA has essentially remained the same (down 0.4% to be exact). The S&P 500 has also
Last month saw the announcement of one the biggest UK M&A (mergers and acquisitions) deals in a while, with Royal Dutch Shell ($RDS.A) set to gobble
Altair Engineering Inc is a provider of enterprise-class engineering software enabling origination of entire product lifecycle from concept design to in-service operation. The integrated suite of software provided by the company optimizes design performance across multiple disciplines encompassing structures, motion, fluids, thermal management, system modeling and embedded systems. The company operates through two reportable segments i.e. Software which includes the portfolio of software products such as solvers and optimization technology products, modeling and visualization tools, industrial and concept design tools, and others; and Client Engineering Services which provides client engineering services to support customers. Most of the company's revenue comes from the United States.
| Website: | www.altair.com |
| Email: | ir@altair.com |
| Main Phone: | +1 248 614-2400 |
| Address: | 1820 East Big Beaver Road |
| State: | MI |
| City / Town: | Troy |
| Country: | USA |
| Postal Code: | 48083 |
| Exchange: | NGS |
| CEO: | James R. Scapa |
| Employees: | 2850 |
| NAICS: | Computer and Computer Peripheral Equipment and Software Merchant Wholesalers(423430) |
Investment decisions should be made to maximize expected total returns relative to risk tolerance.
The most successful consumer goods companies over the past several decades sell products that are used and replaced; are ubiquitous and have a strong brand name.
Yes, there is a difference.
Here's how to turn $4,000 into $1 million...but you have to be patient.
Leading biotechnology company, InVivo Therapeutics, is up 24% following positive developments in their ongoing spinal cord injury study.
It's becoming the equivalent of the "dog ate my homework" excuse during earnings reporting season.
Medical technology is not considered a huge-margin investment in the way that the biotech and drug industries are. However, some of today's medtech blurs the line, including hybrid companies
It's all about the fundamentals for Jason Napodano, CFA, of Zacks Investment Research. Revenue and earnings at the big biotechs are signaling investors that the market is still strong, and
Over the first six months of 2015, the market has not performed very well. Since the 1st of the year, the DJIA has essentially remained the same (down 0.4% to be exact). The S&P 500 has also
Last month saw the announcement of one the biggest UK M&A (mergers and acquisitions) deals in a while, with Royal Dutch Shell ($RDS.A) set to gobble
| Last Price 39.38 | Change $ 0.065 | Change % 0.17 | Tick N/A |
| Bid 39.34 | Bid Size 300.00 | Ask 39.40 | Ask Size 200.00 |
| Open 39.51 | High 39.67 | Low 39.23 | Prev Close 39.31 |
| Last Trade | Volume 94,575 | 52 Wk Hi 43.28 | 52 Wk Low 27.91 |
| Market Cap 2.8 bi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 71,773,832.00 | EPS (TTM) -0.24 | PE Ratio N/A | Exchange NGS |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 0 | 18 |
| Number of Buys | 0 | 16 |
| Number of Sells | 0 | 2 |
| Net Activity | 0 | 73031 |
| Last 10 Buys | Shares |
|---|---|
| N/A | 0 |
| Last 10 Sell | Shares |
|---|---|
| James R. Scapa | 1,000 |
| Danny K. Biran | 1,000 |
| Mark Jon Nelson | 1,000 |
| Jeffrey W. Waters | 1,000 |
| Jeffrey W. Waters | 1,000 |
| Jeffrey W. Waters | 1,000 |
| Jeffrey W. Waters | 1,000 |
| Ronald J. Pasek | 1,000 |
| Mark Jon Nelson | 1,000 |
| Mark Jon Nelson | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 37 | 37 | 37 | 37 |
| Low Target Price Estimate | 30 | 30 | 30 | 30 |
| Mean Target Price Estimate | 33.5 | 33.5 | 33.5 | 33.5 |
| Standard Deviation | 2.74 | 2.74 | 2.74 | 2.74 |
| Date of Most Recent Estimate | 05/15/18 | 05/15/18 | 05/15/18 | 05/15/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-18 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-18 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-18 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-18 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-18 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-18 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-11 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-11 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-11 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-11 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 3 |
| Moderate Buy | 1 | 1 | 1 | 0 |
| Hold | 3 | 3 | 3 | 3 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 2.17 | 2.17 | 2.17 | 2 |
© 2020 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait